@article{3098610,
    title = "Is there a role for alpha(1)-blockers in treating double-J stent-related
symptoms?",
    author = "Deliveliotis, C and Chrisofos, M and Gougousis, E and Papatsoris, A and and Dellis, A and Varkarakis, IM",
    journal = "EMC. Urologie",
    year = "2006",
    volume = "67",
    number = "1",
    pages = "35-39",
    publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",
    doi = "10.1016/j.urology.2005.07.038",
    abstract = "Objectives. To evaluate the effect of alfuzosin in improving symptoms
in, and quality of life of, patients with indwelling double-J ureteral
stents.
Methods. A total of 100 patients, 50 men and 50 women (mean age 54.2
years), with unilateral ureteral stone-related hydronephrosis, who had
opted for conservative management with insertion of a double-J ureteral
stent, were prospectively randomized into two groups. Group 1 included
50 patients who received 10 mg of alfuzosin, once daily for 4 weeks, and
group 2 consisted of 50 patients who received placebo for the same
period. All patients completed a validated Ureteral Stent Symptom
Questionnaire (USSQ) 4 weeks after stent placement.
Results. The mean urinary symptom index score was 21.6 in group 1 and
28.1 in group 2 (P < 0.001). Stent-related pain was reported by 44% of
patients in group 1 and 66% of patients in group 2 (P = 0.027). The
mean pain index score was 14.6 in group 1 and 17.4 in group 2 (P =
0.047). The mean general health index score was statistically greater (P
< 0.001) in group 1 compared with in group 2 (8 versus 11.4,
respectively). Among sexually active patients, the mean sexual score was
2.3 in group 1 and 2.9 in group 2 (P = 0.017).
Conclusions. Stent-related symptoms were present in 66% of the controls
(group 2). Alfuzosin improved a subset of stent-related urinary symptoms
and pain. Patients receiving alfuzosin had their sexual function and
general health better preserved. UROLOGY 67: 35-39, 2006. (c) 2006
Elsevier Inc."
}